Introduction
Clinical risk factors for thrombosis have long been recognized, but only over recent years has laboratory investigation proved fruitful in the identification of abnormalities of coagulation of pathogenic and prognostic importance in thrombotic disease. Thus, deficiency of one of the natural anticoagulants or the presence of antibody to negatively charged phospholipid, as well as a few other disorders, are recognized in a proportion of subjects with thrombotic events and laboratory screening for these abnormalities is now commonplace. The clinical and laboratory aspects of these disorders, the thrombophilias, defined as disturbances of coagulation mechanisms leading to a prethrombotic state, have thus assumed great significance in medical and surgical practice. listed in Table 1 , are known to be associated with a tendency to thrombosis.
Inherited deficiencies of antithrombin and of the vitamin K-dependent anticoagulants protein C and S are undoubtedly linked to a high risk of venous thrombosis, and in homocystinuria arterial thrombosis is common. The evidence relating to some other inherited deficiency states and defects such as heparin cofactor II deficiency, dys-and hypoplasminogenaemia and dysfibrinogenaemia, and to fibrinolytic defects, is less strong however.
Familial antithrombin III deficiency
Antithrombin IIIis a glycoprotein which is synthe- 
Familial thrombophilia
The concept of a familial prethrombotic state is relatively new. Only a few inherited disorders, sized by the liver and has a molecular weight of approximately 50 000. Its name is somewhat misleading in that its inhibitory activity is not confined to thrombin but it is also a potent inhibitor of the other activated clotting factors IXa, Xa, XIa, and XIIa. These are serine proteases, and it is thus the major serine protease inhibitor (Figure 1) .
The inhibition of serine protease activity by antithrombin III is achieved through the formation of a complex which incorporates arginine of antithrombin and serine at the active site of the serine protease. In the absence of heparin, the rate of complex formation, and thus serine protease inhibition, is relatively slow. When heparin is present, complex formation is markedly accelerated.
The physiological significance of this reaction is apparent from the observation that heparan sulphate proteoglycans, which are located at the vascular endothelial cell surface, exert a similar potentiating effect on the rate of complex formation between antithrombin and serine proteases.! Rosenberg-has suggested that this reaction takes place on the vascular endothelial lining and is facilitated through the binding of a small fraction of plasma antithrombin to heparan sulphate proteoglycans at that site. The formation of heparan-antithrombin complexes is thus important, physiologically, in the control of thrombosis.
Prevalence
The association between familial antithrombin deficiency and venous thromboembolism was first recognized in a Norwegian family by Egeberg in 1965 . 3 This initial observation has since been confirmed by other groups from different parts of the world.4-6 The pattern of inheritance of (Antithrombin also inhibits other activated factors -see text.) familial antithrombin deficiency is autosomal dominant. Estimates of its prevalence have ranged widely from 1:350 to 1:30-40 OOO.~The available evidence suggests that it is responsible for approximately 2-5% of venous thromboembolism occurring in adults below the age of 45 years."
Classification of antithrombin deficiency
Until recently the classification of familial antithrombin deficiency was based on results of functional and immunological antithrombin assays. Type I deficiency, accounting for 80-90% of familial antithrombin deficiencies, is characterized by parallel reductions of functional and immunoassays for antithrombin." In individuals with a type II defect a reduced functional antithrombin concentration is associated with normal or near normal concentrations of immunoreactive protein.
Our understanding of the molecular basis of the inherited disorders of antithrombin has been greatly facilitated by the cloning and characterization of the antithrombin gene. 1O -12 It is now recognized that the antithrombin molecule has two important functional domains, namely a thrombin binding domain and a heparin binding domain." Type I defects probably reflect gene mutations producing silent antithrombin alleles, with a reduced plasma concentration of functionally normal antithrombin, whilst type II defects occur as a consequence of point mutations which modify the heparin or thrombin binding properties of the antithrombin molecule, resulting in a functional abnormality.
Two functional assays are employed for the diagnosis of hereditary antithrombin deficiency. These are described as heparin cofactor activity and progressive antithrombin activity. The former measures the rate of inactivation of thrombin or factor Xa by antithrombin in the presence of heparin, the latter determines the proteinase inhibitory activity of antithrombin in the absence of heparin. Since the heparin cofactor assay assesses both of the functional domains of the antithrombin molecule reduced levels are a feature of all antithrombin variants.P Crossed immunoelectrophoresis in the presence of heparin permits the distinction between abnormalities affecting the reactive (thrombin binding) site of the molecule and those involving the heparin binding site. This is of some clinical importance since there is a significant difference in the venous thromboembolic risk between the two groups. Thus, the incidence of venous thromboembolism in individuals with an abnormality affecting the reactive site of the antithrombin molecule is approximately 55% and is similar to that observed in type I defect subjects. This compares with the much lower incidence of 6% in individuals with a defect confined to the heparin binding site.
Clinical features
Venous thromboembolism is the main clinical manifestation of inherited antithrombin deficiency. This is most frequently manifest as deep vein thrombosis but pulmonary embolism is not uncommon. Venous thrombotic events may be recurrent and thrombosis can also occur in unusual sites such as the inferior vena cava, cerebral, mesenteric, portal or renal veins. Some individuals present to dermatologists or to vascular surgeons with the clinical features of the postphlebitic syndrome, including venous ulceration and venous eczema. Thrombophlebitis appears to be less common in individuals with antithrombin deficiency than in those with protein C or protein S deficiency. Although there is often a family history of venous thromboembolism this is not an invariable feature.
Venous thrombosis may be precipitated by trauma or surgery, or it may be associated with pregnancy, oral contraceptive usage or prolonged periods of immobilization. In approximately onethird of subjects there is no apparent precipitating factor."
In individuals with antithrombin deficiency there is a strong association between the venous thrombotic risk and increasing age.s Thus, whilst thrombosis occurs in only 10% of affected children below the age of 15 years this figure rises to approximately 85% by the age of 55 years.s
There are some indications that a relationship exists between antithrombin levels and arterial thrombotic disease. In 1976 Yue et al. 14 reported that high plasma concentrations of antithrombin might predispose to ischaemic heart disease. More recently, Meade et al. , 15 in a prospective study of approximately 900 men, made the fascinating observation that more deaths had occurred in those with antithrombin levels in both the low and high thirds of the normal antithrombin distribution than in individuals whose result fell into the middle third of the pooled results. For men at least, this suggests that both high and low levels of antithrombin may be risk factors for death from arterial disease. The increased risk of arterial thrombosis in an individual with antithrombin deficiency remains to be quantitated, however, and, if present, is certainly much less than the risk of venous thromboembolism.
Acquired antithrombin deficiency may occur in a variety of situations ( Table 2) . A diagnosis of congenital deficiency cannot be reliably made in their presence.
Protein C deficiency
Protein C, a vitamin K-dependent glycoprotein, is a physiologically important inhibitor of the coagulation system. It has a molecular weight of approximately 62 000 and is synthesized by the liver. Protein C is activated on vascular endothelial cell surfaces by a complex formed between thrombin and an endothelium associated protein, thrombomodulin.is Activated protein C then functions as an inhibitor by degrading the activated forms offactors V and VIII ( Figure 1 ). It is noteworthy, therefore, that thrombin activates an anticoagulant system, in addition to its central role in thrombus formation.
Classification and prevalence of protein C deficiency
The relationship between venous thromboembolism and familial protein C deficiency was first reported by Griffin et al. in 1981,17 This association has now been confirmed by other groups. 18, 19 On the basis of functional and immunoreactive protein C assays familial protein C deficiency can be classified into two types. In the more common type I deficiency there is a parallel reduction in both types of assay. Individuals with a type II (variant) defect are characterized by having a normal or near-normal immunoreactive protein C level associated with a reduced functional protein C level, due to synthesis of a defective protein.
In spite of a number of attempts to establish the prevalence of protein C deficiency in the general population the true figure remains unclear. Whereas Broekmans et al. 20 and Gladson et al. 21 reported a prevalence of 1:16000 and 1:36000 respectively, in marked contrast Miletich et al. 22 reported that 1:200-300 healthy blood donors had protein C antigen levels which were consistent with type I deficiency. These marked discrepancies are almost certainly explained by the method of selection. Thus, Broekmans et al. 20 and Gladson et al. 21 produced their results from studies of patients with venous thromboembolism, whereas Miletich et al. 22 derived their figures from healthy subjects with no history of venous thromboembolism.
Clinical features
Venous thromboembolism is the chief clinical There is no difference in the clinical manifestations between individuals with type I and type II deficiency. In an attempt to explain the great variation in clinical severity, subjects with familial protein C deficiency have been divided into two phenotypes: autosomal dominant and autosomal recessive.P In the 'autosomal dominant phenotype', heterozygotes are affected by venous thromboembolism and its complications, whereas heterozygotes for the 'autosomal recessive phenotype' remain asymptomatic. The reason(s) for the differences in clinical expression between the two groups remains unclear. Thrombotic events include deep vein thrombosis, pulmonary embolism and superficial thrombophlebitis. Cerebral venous thrombosis, splanchnic thrombosis and axillary vein thrombosis are described.> Superficial thrombophlebitis is a particularly common manifestation of familial protein C deficiency in 10-57% of heterozygotes.
Thromboembolism may occur at a relatively early age. Broekrnans-> reported that 50% of affected subjects had suffered at least one venous thrombotic event by the age of 30 years and that 80% had become symptomatic by the age of 40 years. Precipitating factors include surgery, oral contraceptives, pregnancy and prolonged periods of immobilization. There may however be no obvious precipitating factor.
Although there are a few reports of arterial thrombosis in subjects with heterozygous protein C deficiency,19,26 there is, to date, no clear evidence that protein C deficiency is a risk factor for arterial thrombovascular disease.
Coumarin-induced skin necrosis is a rare, but important, complication of protein C deficiency.27,28 This probably occurs as a consequence of the rapid fall in protein C levels following the introduction of coumarin therapy. This produces a temporary dissociation between the inhibitory effect of protein C and the procoagulant activities of the vitamin K-dependent clotting factors. The resulting hypercoagulable state results in thrombosis within subcutaneous vessels leading to interstitial bleeding and necrosis of the dermis and subcutaneous fat. Coumarin-induced skin necrosis has also been reported in individuals with acquired protein C deficiency.s? The acquired deficiency, due to failure of synthesis or consumption of protein C, can be found in a range of conditions (Table 2) .
Severe protein C deficiency, due either to homozygous or compound heterozygous protein C deficiency, has been described in children from both Europe and the USA. The clinical manifestations appear to reflect the level of protein C.30 In infants with undetectable levels, purpura fulminans, characterized by disseminated intravascular coagulation and skin necrosis, may develop shortly after birth.P Thrombosis of large vessels without accompanying skin necrosis has been reported in infants with extremely low, but detectable, protein C levels. Neonatal venous thromboembolism is not an invariable manifestation of severe protein C deficiency. Tuddenham et al. ,31 for example, described two affected children who remained symptom free during the neonatal period but developed their first thrombotic episode in the second half of their first year of life. More remarkable were the two subjects described by Tripodi et al. 32 Although they had extremely low levels of protein C, one did not develop venous thrombosis until the age of 28 years while the other remained asymptomatic at the age of 38 years.
Protein S deficiency
Protein S is an important inhibitor of coagulation which functions as a cofactor for activated protein C in the degradation of activated clotting factors V and VIII ( Figure 1 ). It is a vitamin K-dependent protein and is synthesized not only by the liver but also by vascular endothelial cells. Protein S is also present within platelets, In plasma, protein S exists in two forms: free protein S and a complex of protein Sand C4bbinding protein (C4bBP). The former is the biologically active moiety and comprises approximately 35% of the total protein S. The remaining 60-65% of protein S is bound to C4bBP, an acute phase reactant protein, and does not function as a cofactor for activated protein C. 33 ,34 By virtue of its reversible interaction with protein S, C4bBP has an important modulatory role in the cofactor activity of the coagulation inhibitor. Thus, when C4bBP is increased or when total protein S is decreased the high affinity binding between the two proteins results in low plasma levels of free protein S. Conversely, high plasma levels of free protein S are present when the concentration of C4bBP is low. 3s.36
Classification and prevalence of protein S deficiency
Familial protein S deficiency can be classified into three types. In type I deficiency the basic defect is a reduction of total protein S and since the majority of this is bound to C4bBP this results in a corresponding reduction in free protein S. In type II defects total immunoreactive protein S levels are normal as is the equilibrium between free and bound protein S. However, functional protein S activity is impaired. In the least common type III deficiency there is an alteration in the binding between of protein Sand C4bBP resulting in low levels of protein S.3?
Estimates of the prevalence of protein S deficiency in younger subjects presenting with thrombosis have varied between 4 and 8%. 21, 38 To date there are no reliable estimates of the prevalence of the various subtypes of familial protein S deficiency in the general population.
In normal individuals total protein S antigen and free protein S antigen levels are within the range 0.67-1.25 Vlml and 0.23-0.49 Vlml, respectively, with women having slightly lower levels than men. 33 Reduced protein S levels occur in a number of different clinical situations ( Table 2) . It is therefore important to consider and to exclude these acquired protein S deficiencies before establishing a diagnosis of a familial disorder.
Clinical features
The clinical manifestations of familial protein S deficiency are identical to those of inherited protein C deficiency. Venous thromboembolism is thus a striking feature. Superficial thrombophlebitis and deep vein thrombosis are common and account for approximately 60% of thrombotic events. Pulmonary embolism is not uncommon. As with the inherited disorders of antithrombin and protein C, venous thromboembolism may also occur in unusual sites. Reported events include thrombosis within the axillary, mesenteric, portal and cerebral veins. 39. 40 Thrombotic events are frequently recurrent and may occur in association with some precipitating factor such as pregnancy, oral contraceptive usage, surgery, trauma or prolonged periods of immobilization. Thrombosis may also occur apparently spontaneously.
There has been a number of reports of warfarininduced skin necrosis in individuals with protein S deficiency.41-43 All of the described features are indistinguishable from those reported in subjects with familial protein C deficiency, although the mechanism may be different.
As with familial protein C deficiency there are reports of arterial occlusive disease in individuals with inherited protein S deficiency.a-It remains to be established whether this familial disorder is a risk factor for arterial thrombovascular disease.
Clinical management of deficiencies of antithrombin III, protein C and protein S
Acute thrombotic events are treated in the conventional way with intravenous heparin followed by warfarin. Adequate heparinization may be difficult to achieve in some subjects with antithrombin deficiency and the use of antithrombin concentrates should be considered in these patients.
Warfarin is best introduced over three days. To reduce the risk of warfarin-induced skin necrosis in hereditary protein C deficiency, heparin should be continued until the INR is > 2.0. The usual daily loading dose regimen for warfarin is 10, 10, 5 mg, but in elderly patients we suggest the more cautious approach of 10,5,5 mg.
Although there is no universal agreement on the long-term management of patients following an episode of venous thrombosis it would seem reasonable to continue with oral anticoagulants for at least three months. Following pulmonary embolism a longer period of treatment with anticoagulants is usually recommended but the final decision will be influenced by other factors. Thus, lifelong treatment is recommended for a spontaneous pulmonary embolism whereas a shorter period of treatment is suggested if there is an obvious associated or precipitating factor. Women receiving warfarin who are of child-bearing age should remain under constant review and be counselled carefully. In the event of their becoming pregnant the warfarin should be replaced by subcutaneous heparin, at least for the The diagnosis and clinical management ofthrombophilia 123 duration of the first trimester of pregnancy and during the peripartum period.
In familial thrombophilia, and particularly in hereditary protein C and protein S deficiency, there is considerable variability of clinical expression both within and between affected kindreds. Consequently it is not possible to provide precise and standardized guidelines for the prophylactic use of anticoagulants for all affected subjects with familial thrombophilia. Decisions relating to this will be greatly influenced by the subject's personal, social and medical history and also by the clinical circumstances. The diagnosis of familial deficiency, in the absence of thrombosis, is not a sufficient indication for anticoagulant prophylaxis. However, in the event of elective surgery or during periods of prolonged immobilization the prophylactic administration of subcutaneous heparin in affected individuals is strongly recommended. Antithrombin concentrates are now available for the treatment of individuals with antithrombin deficiency and their use should be considered for prophylaxis during surgical procedures. As with all blood products, clotting factor concentrates carry a risk of viral transmission but over the past few years there has been a dramatic improvement in their viral safety and reported events are now rare.
Homocysteinaemia
Currently there is a great deal of interest in the possibility that heterozygotes for familial cystathione beta-synthase deficiency are at risk from both venous and arterial thromboembolism. This rare autosomal recessive disorder is the main cause of homocystinuria and by the age of 30 years approximately 50% of affected individuals have experienced at least one thrombotic event.
The mechanism whereby raised plasma homocysteine induces thrombosis is not yet established but recent evidence suggests that -this could be at least partly due to inhibition of protein C activation by homocysteine at endothelial cell surfaces.s-There is now growing evidence that homocysteinaemia is an independent risk factor for arterial vascular diseaser" It remains to be established whether there is a risk of venous thrombovascular disease in heterozygotes for this enzyme defect.
Acquired thrombophilia
Those acquired conditions in which an increased tendency to thrombosis has been recognized are listed in Table 3 . In some, such as carcinoma, the mechanisms have not been clearly identified, and may include the interplay of a variety of disturbances of coagulation and fibrinolytic mechanisms. Thus, in association with malignancy, increased plasma fibrinogen concentration, thrombocytosis and release of tissue factor may each contribute. Coagulation activation, as well as plasmin generation has been demonstrated. Tumour cell interaction with vascular endothelial cells and with monocytes may also be important. 46 In other situations, especially pregnancy and after tissue trauma, there is considerable evidence for an adaptive intensification of procoagulant mechanisms with a tendency to inhibition of fibrinolytic pathways, together resulting in a prethrombotic state. The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia rubra vera (PRV) are clonal disorders in which unchecked proliferation of myeloid marrow components occurs. In ET arterial and venous thromboembolism occur, often in the presence of only a modest thrombocytosis, of, for example 600 x 10 9/L. The thrombotic risk appears to be greater than that which may accompany reactive thrombocytosis. Paradoxically, in some subjects a haemorrhagic tendency predominates. In PRY the raised blood viscosity, which may be accompanied by a thrombocytosis, results in a high risk of thrombosis, especially stroke and coronary artery occlusion. In atrial fibrillation there is no systemic coagulopathy, but stasis within a noncontracting, often enlarged left atrium allows local thrombosis and systemic arterial embolization. In these disorders the presence of a prethrombotic state may be assumed, and detailed laboratory confirmation is neither required nor routinely possible, although firm diagnosis of ET and PRY requires specialist further investigation. Prophylaxis and treatment is along 'traditional' lines. In contrast, in the 'primary antiphospholipid syndrome' thrombosis may be a presenting feature against a background of good health and unique considerations in relation to laboratory investigation and management arise. These will then be discussed in detail below.
Antlphospholipid antibodies and thrombosis
An acquired prethrombotic state has been associated with the presence in serum of antibodies reactive with negatively charged phospholipids. In our screening programme for the identification of prethrombotic states the detection of such antibodies, by use of coagulation-based tests for the lupus anticoagulant (LA) and solid-phase assays for anticardiolipin (ACL), constitutes a high proportion of positive test results. In contrast to the inherited thrombophilic states, where arterial occlusive disease is an unusual feature, the thrombotic episodes which have been associated with antiphospholipid antibodies (APL) encompass the full range of arterial, venous and microvascular events.
History
Antiphospholipid antibodies (APL) have been identified in various forms for many decades. In 1906 Wassermann described the serologic test for syphilis which uses a lipid extract of syphilitic tissue; this was the first description of an APL. In the more contemporary VDRL, purified beef cardiolipin is used as a substrate, cardiolipin being a major phospholipid component of human mitochondria. The VDRL thus detects an APL induced by syphilitic infection. The 'biological false positive test for syphilis' is due to APL present in autoimmune disease, especially systemic lupus erythematosus (SLE) , first described in 1952. 47 APL may then be present in autoimmune disease as well as in infections. Also in 1952 the 'lupus anticoagulant' (LA) was described.w This is a prolongation of a phospholipid-dependent coagulation test, such as the activated partial thromboplastin time (APTT) , without the presence of an inhibitor against an individual clotting factor or of clotting factor deficiency. It was soon noted that the laboratory abnormality is not associated with a clinical bleeding tendency, and, paradoxically, the presence of such a lupus inhibitor confers a thrombotic risk.
From the above it is apparent that the false positive test for syphilis, anticardiolipin antibody (ACL) and LA all represent antiphospholipid antibodies, the differences apparently lying in phospholipid specificity and in the physical presentation of epitopes, for example as a coagulation-active phospholipid in suspension in clotting assays or cardiolipin in a solid-phase assay.
Laboratory testing for APL
Both coagulation-based assays (for LA) and enzyme-linked immunoassays (ELISA) (for ACL) are employed. Clinical observation suggests that the coagulation assays may be more predictive of thrombosis but we have identified many subjects with high titre ACL and thrombosis but with normal coagulation tests; the significance of a weak positive ACL test alone is, however, in some doubt. Identification of subjects at risk thus demands a comprehensive laboratory approach to diagnosis.
Tests for the lupus anticoagulant (LA)
LA inhibits the formation of the phospholipiddependent complexes in the coagulation cascade ( Figure 1) . It is thus a common cause of prolongation of the APTT. Several tests have been advocated as being sensitive and specific but until recently there has been no consensus on the most appropriate laboratory methodology. A survey in the UK has identified important methodological considerations in detection of the LA and led to recommendations for reliable laboratory testing.s?
Recommended tests and important methodological variables
Whilst the APTT is a useful screening test for LA a weak inhibitor may be missed and it is essential that additional tests be used.s? The test is reagent dependent and it is important to ensure that a screening laboratory is employing a sensitive reagent and appropriate plasma dilution.
Of the possible additional tests the kaolin clotting time (KCT) and the dilute Russell's viper venom time (DRVVT) are particularly sensitive to LA and are recommended. The KCT is essentially an APTf without added phospholipid. The DRVVT relies on the ability of the venom to bypass some of the earlier stages of the coagulation cascade thus concentrating on the relevant phospholipid-dependent step. Specificity in the DRVVT is enhanced by the use of a platelet neutralization procedure in which quenching of the anticoagulant effect by the phospholipid contained in a suspension of freeze-thawed washed platelets is demonstrated.
Detailed recommended methods for the APTf, KCT and DRVVT have been published.50 In our laboratory we employ the APTI and DRVVT, with a platelet neutralization procedure, for detection of LA. In difficult cases we also perform relevant coagulation factor assays to exclude inhibitory activity against a single factor. Clinicians should ensure that appropriate and sensitive tests are being employed. It is also important that fresh plasma is tested and that strenuous efforts are made, by filtration or centrifugation, to remove platelets, as their presence may result in a false negative test result.
Tests for ACL
Sensitive immunoassays for anticardiolipin have been developed and standardized.51 It is usual to test for both IgO and IgM class antibodies using an ELISA technique on serum samples, employing assay plates coated with pure cardiolipin. Interpretation of low positive results is difficult and concordance between laboratories has been pOOr,51 Weak positive tests are of doubtful significance and interpretation should take account of results of coagulation assays for LA and persistence of the abnormalities in repeated tests over a period of weeks or months.
Conditions associated with the presence of APL APL, most commonly ACL but also LA, have been found to be present, sometimes only transiently, in a variety of disease states and conditions as well as in response to drug exposure (Table 4 ). This must be borne in mind in the interpretation of the pathogenic significance of positive tests. The observation that APL antibodies may arise transiently, in infections and after tissue injury such as that occurring in myocardial infarction, suggests that exposure of new antigens may be important in the development of these autoantibodies. Whether these particular APL are associated with a thrombotic tendency is open to doubt. It is also noteworthy that APL may be found incidentally in apparently healthy individuals; in the further investigation of a prolongation of the KCCT in a preoperative coagulation screen the abnormality is not infrequently found to be due to the presence of LA.
The association with thrombosis
In SLE the presence of APL is associated with an increased tendency to thrombotic events, probably of the order of threefold in comparison with SLE sufferers who are negative in the tests. It is now recognized that subjects without features of SLE or other disease may suffer thromboembolic events apparently in association with the presence of positive tests for LA, ACL or both.
In a large series-? the prevalence of thrombotic events was approximately 25% in APL positive subjects both with and without SLE, and these included arterial as well as venous thromboses. Stroke seems to be particularly common, possibly with an embolic basis. In subjects with APL and stroke, heart valve abnormalities, sometimes with noninfective valve vegetations, are frequently detected.P A high risk of recurrent events has been noted.s-Thrombotic events may occur in relatively unusual sites in subjects positive for APL, such as axillary vein thrombosis, sagittal sinus thrombosis, Budd-Chiari syndrome and retinal vein occlusion; frequently the presence of LA or ACL has been the only abnormal laboratory finding. Small vessel occlusion, for example resulting in digital ischaemia, may be present. Dermal vessel involvement leads to a dramatic skin manifestation -livedo reticularis -which is not infrequently seen in subjects with APL and thrombosis, including stroke.s> The characteristic mottled appearance of the skin is most commonly present on the limbs. In rheumatic disorders, especially SLE, thrombocytopenia is strongly associated with elevated ACL titres.
The clinical significance ofAPL
As ACL can appear transiently during an acute infectious episode a single positive test may be unreliable as a marker for thrombosis.56 Furthermore, chronically raised ACL titres observed in some circumstances do not appear to be associated with thrombotic or other events, for example in immune thrombocytopenic purpura and HIY infection. Also, the thrombotic risk associated with drug-induced APL is unclear; in Gastineau's series no thrombotic event was seen in this group,52 whereas others have observed major occlusive events in subjects with drug-induced APL. 57 It may be that LA is a better predictor of thrombotic risk than is ACL. Low titre ACL 
Obstetric associations
Fetal loss, stillbirth and early severe preeclampsia have all been described in association with APL in SLE and also in otherwise healthy women with no serological abnormality other than positive tests for APL. 58.59 In some cases placental infarction is seen but this is not uniformly present and mechanisms other than thrombosis in the placental vasculature may be operative.
We have found a prevalence of 15-20% of LA and a smilar incidence of IgG ACL in women with a history of recurrent (three or more) fetal losses. This compares with much lower figures in women with one or two episodes of fetal loss as well as in over 400 women with normal pregnancy where the prevalence of LA, IgG and IgM ACL was only approximately 1% for each.w
The reproducible finding of APL in a woman with recurrent fetal loss is likely to be of pathogenic significance and thus therapeutic intervention may be helpful, but there is no clinical trial to date on which to base choice of therapy.
The 'antiphospholipid syndrome'
The 'primary antiphospholipid syndrome' refers to subjects without SLE but with APL who may d~v~lop thrombotic, obstetric and perhaps other chmcal problems. It can be defined as the finding of APL (LA or ACL) on at least two occasions eight weeks apart in a subject with history of recurrent fetal loss (three or more), venous thrombosis arterial thrombosis or thrombocytopenia, and without clinical or serological evidence of SLE or related disorder. 61 It is considered that the APL is significant in the development of disease, although cause and effect have not been demonstrated.
Pathogenic mechanisms for thrombosis
The mechanisms whereby APL antibody could produce thrombotic vascular occlusion have not yet been determined, but there are many possibilities, some supported by experimental results.
Damage to vascular endothelial cell membrane could occur, resulting in functional abnormalities of a prethrombotic nature, including reduced prostacyclin synthesis, increased release of von Willebrand factor and surface expression of tissue factor. Platelet activation through membrane interaction is a possibility, and the association between APL and thrombocytopenia is of interest here. Although negatively charged phospholipids are not. ex~osed at the surface of the platelet, after activation by an agonist membrane reorganizati.on coul~al.low their exposure and subsequent antibody bmdmg may augment the aggregation response. Inhibition of fibrinolysis has been reported and we have recently described marked interference in the protein CIS anticoagulant system by I~G preparations from APL subjects.s-The requirement for phospholipid in protein C activation provides a basis for this interference.
It is likely that multiple interactions exist although it must be acknowledged that it remains possible that APL constitutes an epiphenomenon in thrombotic disease and is merely a marker for some as yet undetected defect. Recent work suggests that at least some APL bind to epitot;>es on proteins which become exposed n!y on mteractI~n of the protein with phospholipid. Prothrombin and a natural anticoagulant gl~coprotein (f32-g1ycoprotein I) are two such proterns. They are thus not truly 'antiphospholipid' antibodies. 63 • 64 
Clinical management
There is no controlled clinical trial on the management of thrombosis in association with APL. Those subjects with major venous or arterial thrombosis require anticoagulant therapy in the usual way, with heparin and warfarin. Recurrent thrombosis on discontinuation of anticoagulants has been described and the finding of APL may suggest that long-term anticoagulation is advisable. It is noteworthy that recurrent thrombosis has been described in stroke patients whilst on treatment with oral anticoagulants.s-The prescription of long-term anticoagulant therapy must depend on the perceived risk/benefit ratio in an individual subject. Whether aspirin is effective in prophylaxis remains to be determined but its use could certainly be justified for transient cerebral ischaemic episodes and probably after thrombotic stroke and myocardial infarction. Again, recurrent thrombosis on aspirin has been recorded.s! Other risk factors, such as oral contraceptive usage and smoking, should be avoided. Although the finding of APL may represent an immune mechanism in thrombotic disease immunosuppressive therapy is not indicated unless required for other autoimmune manifestations, as in SLE.
When APL is found incidentally no anticoagulant treatment is indicated. Where abnormal coagulation tests are found preoperatively, the demonstration of LA should allow surgery to proceed safely without haemorrhagic risk provided there is no associated thrombocytopenia. The clinician should though be aware of the rare association between APL and coagulation factor inhibitors, particularly against prothrombin, but also factor VIII.
Only anecdotal data are available on which to base therapeutic decisions in women with APL and recurrent fetal loss. Good results have been claimed for the use of corticosteroids, aspirin, heparin and intravenous immunoglobulin. However, a live infant may result from a subsequent pregnancy, without intervention, even in a woman with a very poor obstetric history. The considerable morbidity associated with corticosteroid usage is best avoided. In women with three or more miscarriages and detectable APL on at least two occasions, we currently recommend prophylaxis with subcutaneous heparin and/or low-dose aspirin for subsequent pregnancies, combined with close liaison with obstetric colleagues and regular assessment of progress using ultrasound scans. Therapy with higher anticoagulant dosage, steroids or intravenous immunoglobulin is reserved for women who have evidence of fetal growth retardation, or where use of aspirin/heparin fails to result in a favourable outcome, but it is acknowledged that none of these approaches is yet of proven value.
Screening for thrombophilia
In the majority of instances thrombotic disease occurs against a background of predisposing diseases or situations which would render a search for thrombophilic states unfruitful and prohibitively expensive. However, where screening is confined to a few relatively uncommon clinical situations, the diagnostic reward is sufficiently high to justify testing ( Table 5 ). We would recommend screening in these situations, as appropriate counselling and therapeutic decisions may well be influenced by the results. For the precise diagnosis of important thrombophilic states, a comprehensive range of laboratory tests is required (Table 6 ). 
Conclusions
It is important that consideration be given to the possible diagnosis of a thrombophilic state in some subjects presentingwith vascularocclusive disease. A comprehensive laboratory and clinical approach will lead to rational clinical management.
